| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PHARMTHERA.2004.10.010 |
| P698 | PubMed publication ID | 15737408 |
| P2093 | author name string | M Catherine Bennett | |
| P2860 | cites work | Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 |
| Parkinsonism: a clinical marker of exposure to neurotoxins | Q39573876 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Synuclein | Q24767155 |
| neurodegeneration | Q1755122 | ||
| P304 | page(s) | 311-331 | |
| P577 | publication date | 2004-12-08 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | The role of alpha-synuclein in neurodegenerative diseases | |
| P478 | volume | 105 |
| Q92927768 | APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer's disease pathophysiology |
| Q46666592 | Acridine derivatives inhibit lysozyme aggregation. |
| Q42444692 | Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus. |
| Q37386416 | Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. |
| Q35139572 | Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review |
| Q48274235 | Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease |
| Q36554589 | Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease |
| Q37020862 | Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? |
| Q30424486 | Anesthesia-induced developmental neurodegeneration: the role of neuronal organelles |
| Q64865563 | Asiatic Acid Prevents Oxidative Stress and Apoptosis by Inhibiting the Translocation of α-Synuclein Into Mitochondria |
| Q24323344 | Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein |
| Q36520931 | Catabolic insufficiency and aging |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q43256880 | Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein |
| Q37715960 | Computational approaches to understanding protein aggregation in neurodegeneration |
| Q64123712 | Conservation of the Amyloid Interactome Across Diverse Fibrillar Structures |
| Q48440013 | Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. |
| Q33755817 | DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity |
| Q33715071 | Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study |
| Q90738392 | Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders |
| Q34656396 | EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers |
| Q35681438 | Effect of lysosomal and ubiquitin-proteasome system dysfunction on the abnormal aggregation of α-synuclein in PC12 cells |
| Q43169449 | Effects of dithiothreitol on the amyloid fibrillogenesis of hen egg-white lysozyme |
| Q28732131 | Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1 |
| Q37232067 | Immunological features of alpha-synuclein in Parkinson's disease |
| Q39368611 | Impact of Non-Enzymatic Glycation in Neurodegenerative Diseases: Role of Natural Products in Prevention. |
| Q28283547 | Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease |
| Q35172657 | Improved immunodetection of endogenous α-synuclein |
| Q36872892 | Interactions between metals and alpha-synuclein--function or artefact? |
| Q48485896 | Intranigral dopamine toxicity and alpha-synuclein response in rats. |
| Q38044422 | Intrinsic disorder in proteins: a challenge for (un)structural biology met by ion mobility-mass spectrometry |
| Q46173279 | Lessons learned from protein aggregation: toward technological and biomedical applications. |
| Q34478663 | Lewy bodies |
| Q37079830 | Lysosomes in iron metabolism, ageing and apoptosis |
| Q35992475 | Macrophages associated with the intrinsic and extrinsic autonomic innervation of the rat gastrointestinal tract |
| Q33366459 | Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases |
| Q36727241 | Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain |
| Q37556779 | Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases |
| Q37570507 | Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging |
| Q31165000 | Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers |
| Q24298523 | Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein |
| Q37350413 | Molecular and cellular biology of synucleins |
| Q37472670 | Molecular mechanism of active zone organization at vertebrate neuromuscular junctions |
| Q37003479 | Multiple system atrophy: alpha-synuclein and neuronal degeneration |
| Q34648491 | Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation |
| Q47097416 | Omics Approaches for Identifying Physiological Adaptations to Genome Instability in Aging |
| Q39716036 | Oxidative stress partially contributes to iron-induced α-synuclein aggregation in SK-N-SH cells |
| Q39416222 | Parkinson's disease: genetics and beyond |
| Q48246699 | Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease |
| Q42958291 | Photo-activity induced by amyloidogenesis |
| Q37166339 | Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element |
| Q38923732 | Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction |
| Q24311624 | Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions |
| Q35241298 | Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome |
| Q38028366 | Rifampicin and Parkinson's disease |
| Q36731472 | Role of Ser129 phosphorylation of α-synuclein in melanoma cells |
| Q37587111 | Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation |
| Q30357845 | Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation |
| Q38039857 | Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration |
| Q30422273 | The abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: the importance of free oxygen radicals and mitochondrial integrity |
| Q46316816 | The long noncoding RNA Malat1: Its physiological and pathophysiological functions |
| Q37809751 | Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease |
| Q40274137 | gamma-synuclein has a dynamic intracellular localization |
| Q28572683 | α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity |
| Q38947516 | α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease |
| Q33889446 | α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. |
Search more.